Clinical Trial Update: Double Blind Comparative Study of TAK-875 [Phase 3]

View source ↗

Summary

A Phase 3 double-blind comparative study of TAK-875 in diabetic patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TAK-875 (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Diabetic Patients | Phase 3 | Status: COMPLETED